Bio­gen flags de­lays on Spin­raza treat­ments as hos­pi­tals shift fo­cus and re­sources to pan­dem­ic pa­tients

The pan­dem­ic is start­ing to in­ter­rupt the flow of Bio­gen’s life­sav­ing block­buster Spin­raza to SMA pa­tients.

The big biotech not­ed in a state­ment that some health sys­tems are post­pon­ing treat­ment as they set about the com­plex busi­ness of shift­ing re­sources to fight the pan­dem­ic. In the state­ment, Bio­gen not­ed:

We are aware that some pa­tients treat­ed with SPIN­RAZA are tem­porar­i­ly hav­ing their dos­ing post­poned as part of health sys­tem ef­forts to pri­or­i­tize po­ten­tial COVID-19 pa­tients. We are work­ing with health sys­tems and in­sti­tu­tions to help nav­i­gate these un­prece­dent­ed times while al­so pro­vid­ing ac­cess to a crit­i­cal ther­a­py for peo­ple with SMA. We al­so want­ed to point you to guid­ance shared yes­ter­day from Cure SMA re­lat­ed to COVID-19 that ad­dress­es this is­sue.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.